Core Viewpoint - The company reported a significant decline in revenue and a net loss for the first half of 2025, indicating financial challenges and a shift from profitability to loss compared to the previous year [1] Financial Performance - The company's operating revenue for the reporting period was 4.919 billion yuan, representing a year-on-year decrease of 73.06% [1] - The net profit attributable to shareholders was a loss of 0.597 billion yuan, contrasting with a profit of 2.234 billion yuan in the same period last year, marking a significant year-on-year decline [1] Dividend Policy - The company announced plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]

Core Points - Zhifei Biological's subsidiary, Beijing Zhifei Lvzhu, has received the clinical trial application acceptance notice from the National Medical Products Administration for its self-developed acellular pertussis-diphtheria-tetanus (Tdap) combined vaccine for adults and adolescents, marking a significant breakthrough in the multi-valent vaccine development field [1] Group 1 - The vaccine aims to fill the market gap for adult and adolescent booster immunization against pertussis, diphtheria, and tetanus in China [1]

Core Viewpoint - The company reported a significant decline in revenue and incurred a net loss in the first half of 2025, attributed to decreased public vaccination willingness and changing market demand [1] Financial Performance - The company achieved an operating revenue of 4.919 billion yuan in the first half of 2025, representing a year-on-year decrease of 73.06% [1] - The net profit attributable to the parent company was a loss of 597 million yuan, compared to a net profit of 2.234 billion yuan in the same period last year [1]

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary has received approval for clinical trials of a new acellular DTP vaccine for adults and adolescents, filling a gap in the market for this demographic in China [1] Group 1: Company Developments - Zhifei Biological's wholly-owned subsidiary, Beijing Zhifei Green Bamboo Biological Pharmaceutical Co., Ltd., has developed an acellular DTP (Diphtheria, Tetanus, Pertussis) combined vaccine [1] - The vaccine is intended for healthy individuals aged 7 and above to prevent whooping cough, diphtheria, and tetanus [1] - The National Medical Products Administration has accepted the drug clinical trial application, allowing clinical trials to commence if no objections are raised within 60 days [1] Group 2: Market Context - Currently, there are no approved acellular DTP vaccines available for adolescents and adults in the domestic market [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 智飞生物(300122.SZ)公告称，智飞生物发布2025年半年度报告，报告期内，公司营业收入为49.19亿 元，同比下降73.06%，归属于上市公司股东的净利润为亏损5.97亿元，上年同期盈利22.34亿元，同比 转亏。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Core Viewpoint - The announcement by Zhifei Biological (300122) regarding the acceptance of the clinical trial application for its acellular DTP vaccine for adolescents and adults indicates a significant market opportunity as there are currently no approved vaccines for this demographic in China [1] Group 1 - Zhifei Biological's wholly-owned subsidiary, Zhifei Green Bamboo, has developed a vaccine suitable for individuals aged 7 and above to prevent whooping cough, diphtheria, and tetanus [1] - The vaccine has received the acceptance notice from the National Medical Products Administration for drug clinical trial application [1] - The absence of approved acellular DTP vaccines for adolescents and adults in the domestic market highlights the broad market potential for this product [1]

智飞生物公告，2025年上半年营业收入49.19亿元，同比下降73.06%。净利润亏损5.97亿元，上年同期 净利润为22.34亿元。报告期内，受民众接种意愿下降、市场需求变化等多重因素影响，公司与默沙东 协商一致，调整了本年度HPV疫苗的采购与供应节奏，并持续开展需求评估以共同应对市场变化。 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-49 重庆智飞生物制品股份有限公司 关于吸附无细胞百白破（组分）联合疫苗（成人及青少年用） 临床试验申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 智飞绿竹研发的青少年及成人组分百白破疫苗是新一代的无细胞百白破疫 苗，系采用单独纯化的百日咳有效组分，联合白喉、破伤风有效组分配制出的质 1 量均一的疫苗产品，适用于 7 岁及以上健康人群预防百日咳、白喉、破伤风。截 至目前，国内暂无可供青少年及成人使用的组分百白破疫苗获批上市，市场前景 广阔。 公司积极响应国家鼓励研发多联多价疫苗的号召，发挥技术创新优势，在研 管线中吸附无细胞百白破（组分）联合疫苗处于 III 期临床试验中，组分百白破 -Hib 四联疫苗已获得临床试验批准通知书。青少年及成人组分百白破疫苗临床试 验申请获得受理亦是公司聚焦创新技术、增强科研攻关的成果。若本项目进展顺 利，将进一步夯实公司多联疫苗矩阵布局，强化公司的市场竞争优势，为实现长 远目标奠定坚实基础。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：重庆智飞生物制品股份有限公司 单位：万元 | 非经营性资金占 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核 算的会计科 | 2025 年期初占 | 年 月占 2025 1-6 用累计发生金额 | 年 2025 1-6 占用资金的利 | 月 2025 | 年 1-6 月偿 | 2025 年6 月末 | 占用 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用 | | 关联关系 | 目 | 用资金余额 | （不含利息） | 息(如有） | | 还累计发生金额 | 占用资金余额 | 形成原因 | | | 现大股东 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | 前大股东 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-47 重庆智飞生物制品股份有限公司 第六届监事会第六次会议决议公告 二、监事会会议审议情况 经过认真审议，本次会议形成了如下决议： 1、审议通过了《<2025 年半年度报告>及<2025 年半年度报告摘要>》 经审核，监事会认为：董事会编制和审核公司 2025 年半年度报告及摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见当日发布在中国证监会指定信息披露网站巨潮资讯网的公司 《2025 年半年度报告》及《2025 年半年度报告摘要》。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会于 2025 年 8 月 6 日以电子邮件的方式向监事发出通知。 2、本次会议于 2025 年 8 月 15 日 11:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的监事 3 人，实际出席并参加表决的监事 3 人。 4、本次会议由公司监事会主席荀 ...